Sanofi’s Dupixent Shows Promise in Phase III Trials for Rare Skin Disease and Chronic Hives
Sanofi (EPA: SAN; NASDAQ: SNY), a leading French pharmaceutical company, has announced positive results from...
FDA Uncovers Data Management Failures in Medical Device Labs, Assessing Regulatory Impact
Medical device manufacturers relying on laboratory services for testing and validation data have come under...
Oxford Nanopore Sets Sights on BGI in UK Courts Over Nanopore Sequencing Technology
Oxford Nanopore Technologies plc (LON: ONT), a UK-based leader in nanopore sequencing technology, has disclosed...
Luye Pharma’s Subsidiary Boan Biotech Partners with Haier Biomedical for Pharmaceutical Industry Digitalization
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced a...
Signet Therapeutics and Jennio Biotech Join Forces to Advance Tumor Immunotherapy
Signet Therapeutics, a pioneering biopharmaceutical company in China specializing in cancer targeted therapies based on...
China Aims to Fortify Insurance Industry by 2035 with New State Council Directives
The State Council has issued the “Several Opinions on Strengthening Supervision, Preventing Risks, and Promoting...
Suzhou GenAssist Launches First-of-Its-Kind Base Editing Drug Trial for Duchenne Muscular Dystrophy
Suzhou GenAssist Therapeutic Co., Ltd, a biopharmaceutical company based in China, has announced the commencement...
Siemens Healthineers’ 7T MRI System Terra. X Receives NMPA Marketing Approval
Siemens Healthineers AG has secured marketing approval from China’s National Medical Products Administration (NMPA) for...
Innovent Biologics’ Mazdutide Outperforms Dulaglutide in Phase III T2D Study at EASD Meeting
Innovent Biologics, Inc. (HKG: 1801), a biopharmaceutical company based in China, has presented significant findings...
CSA Medical Inc. Secures USD 53 Million in Series D Financing to Advance Cryotherapy Treatment
CSA Medical Inc., a U.S.-based medical technology company, has successfully closed a Series D financing...
Celltrion Inc. Enters CDMO Arena Amid Shifts in Global Biosecurity Landscape
South Korea’s biosimilars giant, Celltrion Inc., is gearing up to expand into the contract development...
Gilead Sciences Partners with AI Firm Genesis Therapeutics to Develop Novel Small-Molecule Therapies
Gilead Sciences Inc. (NASDAQ: GILD), a biopharmaceutical company based in the U.S., has entered into...
Carisma Therapeutics and Moderna Expand Partnership to Target Autoimmune Diseases with CAR-M Therapies
Carisma Therapeutics Inc. (NASDAQ: CARM), a U.S.-based company specializing in chimeric antigen receptor (CAR) macrophage...
Itcure Expands Gene Editing Reach with Collaborations in China’s Biotech Sector
Itcure, a prominent gene editing specialist headquartered in Suzhou, has announced separate strategic collaborations with...
Qilu Pharmaceutical’s Iruplinalkib Shows Promising Results in Phase II Study for ALK+ NSCLC
Qilu Pharmaceutical, a leading pharmaceutical company based in China, has presented updated results from the...
ImmuneOnco Receives Second Payment from Instil Bio, Highlighting Ongoing Licensing Deal
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the receipt of a further payment...
Nuance Pharma Completes Enrollment for Phase III COPD Trial of Ohtuvayre in China
Nuance Pharma, a China-based pharmaceutical company, has announced the completion of patient enrollment for the...
Innovent Biologics Presents Promising Phase I Data for IBI363 in Advanced NSCLC at WCLC
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has unveiled Phase...
Betta Pharmaceuticals’ MCLA129 for Advanced Solid Tumors Accepted for Review by China’s NMPA
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a pharmaceutical company based in China, has announced that...
Duality Biologics Initiates Global Clinical Trial for DB-1419 in Advanced Solid Tumors
Duality Biologics, Inc., a biopharmaceutical company based in China, has reached a significant milestone with...